¥1,836.00
2.70% today
Tokyo, Oct 10, 08:15 am CET
ISIN
JP3495000006
Symbol
4506
Index

Sumitomo Dainippon Pharma Target price 2025 - Analyst rating & recommendation

Sumitomo Dainippon Pharma Classifications & Recommendation:

Buy
55%
Hold
27%
Sell
18%

Sumitomo Dainippon Pharma Price Target

Target Price ¥1,377.00
Price ¥1,887.00
Deviation
Number of Estimates 9
9 Analysts have issued a price target Sumitomo Dainippon Pharma 2026 . The average Sumitomo Dainippon Pharma target price is ¥1,377.00. This is lower than the current stock price. The highest price target is
¥1,995.00 5.72%
register free of charge
, the lowest is .
A rating was issued by 11 analysts: 6 Analysts recommend Sumitomo Dainippon Pharma to buy, 3 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sumitomo Dainippon Pharma stock has an average upside potential 2026 of . Most analysts recommend the Sumitomo Dainippon Pharma stock at Purchase.

Sales and Margin forecast 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Revenue Billion ¥ 398.83 421.82
26.79% 5.76%
EBITDA Margin 9.70% 25.97%
121.51% 167.61%
Net Margin 5.93% 15.52%
105.92% 161.91%

8 Analysts have issued a sales forecast Sumitomo Dainippon Pharma 2026 . The average Sumitomo Dainippon Pharma sales estimate is

¥422b
Unlock
. This is
1.36% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
¥464b 11.47%
Unlock
, the lowest is
¥393b 5.57%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 ¥399b 26.79%
2026
¥422b 5.76%
Unlock
2027
¥478b 13.26%
Unlock
2028
¥472b 1.21%
Unlock

8 Analysts have issued an Sumitomo Dainippon Pharma EBITDA forecast 2026. The average Sumitomo Dainippon Pharma EBITDA estimate is

¥110b
Unlock
. This is
40.95% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
¥132b 70.11%
Unlock
, the lowest is
¥90.2b 16.02%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 ¥38.7b 127.27%
2026
¥110b 182.99%
Unlock
2027
¥110b 0.44%
Unlock
2028
¥83.2b 24.41%
Unlock

EBITDA Margin

2025 9.70% 121.51%
2026
25.97% 167.61%
Unlock
2027
23.03% 11.32%
Unlock
2028
17.62% 23.49%
Unlock

8 Sumitomo Dainippon Pharma Analysts have issued a net profit forecast 2026. The average Sumitomo Dainippon Pharma net profit estimate is

¥65.5b
Unlock
. This is
246.43% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
¥83.5b 341.58%
Unlock
, the lowest is
¥49.0b 159.22%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 ¥23.6b 107.50%
2026
¥65.5b 177.08%
Unlock
2027
¥63.8b 2.59%
Unlock
2028
¥34.2b 46.38%
Unlock

Net Margin

2025 5.93% 105.92%
2026
15.52% 161.91%
Unlock
2027
13.35% 13.98%
Unlock
2028
7.25% 45.69%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Earnings Per Share ¥ 59.49 164.83
107.50% 177.07%
P/E 11.45
EV/Sales 2.42

8 Analysts have issued a Sumitomo Dainippon Pharma forecast for earnings per share. The average Sumitomo Dainippon Pharma EPS is

¥164.83
Unlock
. This is
246.43% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
¥210.11 341.59%
Unlock
, the lowest is
¥123.34 159.23%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 ¥59.49 107.50%
2026
¥164.83 177.07%
Unlock
2027
¥160.55 2.60%
Unlock
2028
¥86.09 46.38%
Unlock

P/E ratio

Current 39.66 4,391.69%
2026
11.45 71.13%
Unlock
2027
11.75 2.62%
Unlock
2028
21.92 86.55%
Unlock

Based on analysts' sales estimates for 2026, the Sumitomo Dainippon Pharma stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.45 58.06%
2026
2.42 1.40%
Unlock
2027
2.13 11.71%
Unlock
2028
2.16 1.23%
Unlock

P/S ratio

Current 1.79 137.53%
2026
1.77 1.34%
Unlock
2027
1.56 11.71%
Unlock
2028
1.58 1.23%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today